Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-1293 Compared With a Basal Insulin in Participants With Type 1 Diabetes (MK-1293-005)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Has type 1 diabetes mellitus diagnosed at least 12 months before screening~* Subject to investigator discretion, is on a stable dose of insulin for at least 2 weeks before screening~* Has a total daily insulin dose \<=1.2 units/kg~* Has a screening hemoglobin A1c \<9.5%~* Has a body mass index \>18.0 and \<=30.0 kg/m\^2~* Has a weight \>=50 kg~* Female participant of reproductive potential has a serum beta-human chorionic gonadotropin level consistent with the nongravid state and agrees to use (and/or have her partner use) 2 acceptable methods of birth control until 2 weeks after the last dose of study drug~* Postmenopausal female participant is without menses for \>=1 year~* Surgically sterile female participant status is post hysterectomy, oophorectomy, or tubal ligation~* Has not used nicotine or nicotine-containing products for at least 3 months before study start or smokes less than 10 cigarettes per day and is willing to abstain during the trial~Exclusion Criteria:~* Has a history of clinically significant gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological abnormalities or disease~* Has a history of clinically significant endocrine abnormalities or diseases except type 1 diabetes mellitus~* Has had any severe hypoglycemic episodes associated with hypoglycemic seizures, comas, or unconsciousness within the past 3 months~* Has a history of diabetic ketoacidosis within the past 6 months~* Has a history of significant multiple or severe allergies, anaphylactic reaction, or significant intolerability to drugs or food~* Has a history of hypersensitivity to pharmacologic insulins~* Is positive for hepatitis B surface antigen, hepatitis C, or Human Immunodeficiency Virus~* Has had major surgery or donated or lost 1 unit of blood within 4 weeks before screening~* Unable to refrain from use of any medication or herbal remedy from 2 weeks prior to the first dose of study drug to until the posttrial visit. Some medications are permitted and may be discussed with the investigators~* Vaccination within 12 weeks of start of study participation~* Consumes \>3 glasses of alcoholic beverages per day. Participants consuming 4 glasses of alcoholic beverages may be enrolled at the discretion of the investigator.~* Consumes \>6 servings of caffeinated beverages per day~* Is a regular user of any illicit drugs or has a history of drug abuse (including alcohol) within approximately 1 year~* Is on a carbohydrate-restricted diet (\<100 grams carbohydrate per day); participants who are on a carbohydrate-restricted diet may be included if they agree to a diet consisting of \>=100 grams of carbohydrate daily throughout the study~* Has a personal or family history of hypercoagulability or thromboembolic disease~* Has used systemic glucocorticoids within 3 months of screening or anticipates treatment with systemic glucocorticoids during study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- MK-1293 / EU-Lantus™ / MK-1293 / EU-Lantus™ (Type: EXPERIMENTAL): MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period
- EU-Lantus™ / MK-1293 / EU-Lantus™ / MK-1293 (Type: EXPERIMENTAL): MK-1293 or EU-Lantus™ 0.4 units/kg administered subcutaneously on Day 1 in 2 out of 4 study periods in a replicate crossover design with a minimum of 7 days between each treatment period

Based on this trial design, predict the completion outcome and termination type (if applicable).